- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Multiplex Assays Market by Product & Service (Consumable, Instrument), Type (Protein, Nucleic Acid), Technology (Flow Cytometry), Application [R&D, Diagnostics (Infectious Disease, Cancer)], End User (Hospital, Research Institute)-Global Forecast to 2031
USD 10.65 BN
MARKET SIZE, 2031
MULTIPLEX ASSAYS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global multiplex assay market is projected to grow from USD 7.15 billion in 2026 to USD 10.65 billion by 2031, at a CAGR of 8.3% during the forecast period. The market was valued at USD 6.65 billion in 2025. The use of multiplex assays is driven by the need for laboratories to manage a growing number of samples, reduce turnaround times, and address increasingly complex disease mechanisms. There is particularly high demand for methods that extract multiple biomarkers from a single sample.
KEY TAKEAWAYS
-
BY REGION
The Asia Pacific region is expected to experience the fastest growth, driven by the expansion of laboratory capacity, increased use of molecular testing, and ongoing funding in countries like China, India, and Japan. Meanwhile, North America is projected to maintain the largest revenue base in 2025, owing to established suppliers and well-developed diagnostic networks.
-
BY PRODUCT & SERVICE
By product & service, consumables accounted for the largest share of 67.9% in 2025, primarily because they are included in every testing cycle rather than being linked to one-time capital purchases.
-
BY TYPE
By type, protein multiplex assays are expected to register the highest CAGR of 8.6% during the forecast period.
-
BY TECHNOLOGY
By technology, multiplex real-time PCR is expected to dominate the market in 2025 because of its broad application in immune profiling and cell analysis.
-
BY APPLICATION
By application, the research & development segment accounted for the largest market share of 61.6% in 2025.
-
BY END USER
By end user, pharmaceutical & biotechnology companies are projected to witness the highest CAGR due to increasing use in companion diagnostics and clinical research.
-
COMPETITIVE LANDSCAPE - KEY PLAYERS
Thermo Fisher Scientific, Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), DiaSorin S.p.A. (Italy), Revvity, Inc. (US), and bioMérieux (France) were identified as star players, which correspondingly are supported by their strong market presence and extensive product portfolios.
-
COMPETITIVE LANDSCAPE - STARTUPS/SMEs
Randox Laboratories Ltd. (UK), Standard BioTools (US), Promega Corporation (US), Boster Biological Technology (US), and Enzo Biochem Inc. (US) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas.
The multiplex assay market is experiencing steady growth due to the rising incidence of infectious diseases, cancer, and autoimmune conditions. This increase is expanding routine testing volumes and putting pressure on traditional single-target workflows. Additionally, precision medicine programs are gaining traction, as treatment pathways increasingly depend on biomarker stratification. Notably, the smaller sample requirements of multiplex formats make them particularly appealing in pediatrics and specialty care.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The influence of consumers on the multiplex assay market is driven by trends in healthcare demand, testing methodologies, and disruptions in diagnostic testing. Key end users of multiplex assay providers include hospitals, diagnostic centers, pharmaceutical & biotech companies, educational institutions, and contract research organizations (CROs). High-potential applications in this market include infectious diseases, cancer, autoimmune diseases, biomarkers, and companion diagnostics.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
OPPORTUNITIES
Impact
Level
-
Growing validation of biomarkers in molecular and protein-based diagnostics
-
Expansion in emerging markets
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The use of precision medicine in everyday practice has become increasingly common, driving a growing demand for multiplex tests as companion diagnostics. These multiplex tests enable the detection of multiple biomarkers from small or suboptimal biological samples. Additionally, drug developers are utilizing multiplex formats to improve patient selection and minimize inefficiencies in clinical trial screening. Importantly, a well-designed panel can significantly reduce the time between diagnosis and treatment decision.
There are still fundamental economic problems to address, such as ownership costs. Multiplex solutions will likely require upfront capital investment, which might prove problematic for smaller labs, independent diagnostic centers, and financially struggling hospitals. Apart from the upfront cost, there are service agreements, calibration procedures, middleware compatibility, reagent validation, and training costs.
Multiplex assays benefit from the emergence of a steady stream of clinically relevant markers. What researchers require now is a tool that allows the analysis of genetic, proteomic, and immune response biomarkers all together, instead of studying each one individually. This is where multiplex assays play a critical role, especially when working in oncology, autoimmune disorders, and longitudinal monitoring. Not so widely recognized is the usefulness of these assays for early assay screening and exclusion.
The adoption of technology often hinges more on the availability of skilled personnel than on the presence of equipment. In the case of multiplex assays, having knowledgeable staff is essential for proper assay setup, contamination prevention, result interpretation, and troubleshooting any equipment issues. Unfortunately, this skilled workforce is still lacking, especially in rural areas.
MULTIPLEX ASSAYS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Widely used for multiplex qPCR and immunoassay testing across infectious disease screening, oncology biomarker studies, and translational research programs where multiple analytes must be measured quickly from limited samples. | Generates demand from clinical laboratories and research centers seeking faster throughput, lower hands-on time, and consolidation of several single-target assays into one workflow. |
|
|
Uses next-generation sequencing (NGS)-based multi-panel approaches to perform genomic profiling, hereditary disorders testing, companion diagnostics, and cancer panels that demand comprehensive biomarker detection in one run. | Supports premium-value testing with higher information yield per sample. Notably, laboratories can reduce repeat testing, while pharmaceutical partnerships and oncology adoption create durable revenue channels. |
|
|
Supplies droplet digital PCR and multiplex immunoassay systems for mutation detection, gene expression analysis, residual disease monitoring, and quantitative biomarker research. | Enhances sensitivity, enables accurate quantification, and supports reproducible research outcomes. |
|
|
Focuses on multiplex molecular panels for respiratory infections, gastrointestinal pathogens, and healthcare-associated infections in acute care settings. | Creates value through faster syndromic diagnosis and reduced empiric treatment decisions | Hospitals often justify adoption through shorter isolation periods, better bed management, and improved laboratory efficiency. |
|
|
Known for multiplex syndromic tests that include sepsis, respiratory, blood stream infection, and AMR markers. | Greatest traction achieved when timely results impact patient care and treatment | Timely pathogen detection can minimize use of unnecessary antibiotics, which has become an important buying point. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The value chain for multiplex assays comprises a multilayered structure that includes consumable providers such as Merck KGaA and Thermo Fisher Scientific, platform providers such as Bio-Rad Laboratories and DiaSorin, and end users, including hospitals, clinical laboratories, pharmaceutical companies, and academic institutions. The components involved—such as beads, antibodies, primers, calibrators, and various chemistries—are integrated into platforms that measure multiple biomarkers in a single assay. Demand for these assays primarily comes from hospitals, laboratories, biopharmaceutical companies, and academic institutions, all of which require high throughput and precision. Additionally, although often overlooked, software interoperability is becoming increasingly important in purchase decisions, often competing with assay performance.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
As of 2025, consumables hold the largest share of the multiplex assay market and are expected to remain dominant through 2026. This is driven by the ongoing demand for assay kits, reagents, beads, plates, and cartridges. The frequent use of tests in diagnostics and research leads to repeat purchases, while the continuous introduction of new panels enhances long-term revenue prospects on a global scale.
As of 2025, protein multiplexing is expected to be the leading contributor to the market, with this trend projected to continue until 2026. This growth is driven by its extensive use in cytokine profiling, biomarker testing, immunohistochemistry, and cancer research applications. Bead-based and planar platforms enable the simultaneous measurement of multiple proteins from small sample sizes. The increasing demand for precision medicine and translational research continues to support steady expansion in this segment worldwide.
As of 2025, the multiplex real-time PCR segment leads the global multiplex assay market in terms of revenue and is projected to remain dominant through 2026. This leadership is due to its high sensitivity and capability for multi-parameter analyses, along with its widespread use in laboratories for immunological monitoring, cellular phenotyping, and biomarker detection.
By 2025, the research & development sector is expected to be the leading application category due to the increasing adoption of multiplex diagnostic tests for infectious diseases, cancer, autoimmune diseases, and cardiovascular diseases.
As of 2025, pharmaceutical & biotechnology companies hold the largest share of the multiplex assay market. This is due to high patient volumes, established testing infrastructure, and a growing demand for rapid diagnostics. These companies are increasingly adopting multiplex platforms to enhance turnaround times, improve workflow efficiency, and aid clinical decision-making in both routine and specialized testing.
REGION
Asia Pacific to be fastest-growing region in global multiplex assay market during forecast period
The Asia Pacific region is expected to experience the highest CAGR over the coming years, driven by improvements in healthcare facilities, a high incidence of infections requiring testing, and increased investment in advanced diagnostic techniques. Notable countries experiencing these trends include China, Japan, India, and South Korea. Other factors contributing to market growth include advancements in drug manufacturing and improved accessibility to testing solutions.
MULTIPLEX ASSAYS MARKET: COMPANY EVALUATION MATRIX
In the multiplex assay market, Thermo Fisher Scientific, Inc. (US) stands out as a dominant player, owing to its extensive assay portfolio, global distribution capabilities, and expertise in molecular diagnostics, immunoassays, and life science products. In contrast, F. Hoffmann-La Roche Ltd. (Switzerland) is positioned as an emerging leader, enhancing its market presence by developing innovative PCR-based multiplex assays. While Thermo Fisher benefits from its size, the consistent demand for consumables, and a diverse product offering, Roche demonstrates significant potential to advance into the leaders’ quadrant through an expanded product menu and solutions focused on automation.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific, Inc. (US)
- Illumina, Inc (US)
- Bio-Rad Laboratories, Inc. (US)
- DiaSorin S.p.A. (Italy)
- bioMérieux (France)
- QIAGEN N.V. (Netherlands)
- Danaher Corporation (US)
- Becton, Dickinson and Company (US)
- Merck KGaA (Germany)
- Revvity, Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Agilent Technologies (US)
- Quanterix Corporation (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 6.65 Billion |
| Market Forecast in 2031 (Value) | USD 10.65 Billion |
| Growth Rate | CAGR of 8.3% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion), Volume (Units) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: MULTIPLEX ASSAYS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Country-wise analysis of multiplex assay market across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa | Detailed analysis and profiling of up to five additional market players | Expanded competitive landscape assessment with profiling and analysis of 25 key companies operating in the multiplex assay market, highlighting recent product developments, strategic investments, partnerships, and market positioning |
| Market share analysis and competitive benchmarking of key multiplex assay companies | Further breakdown of the multiplex assay market into specific countries for the Rest of Europe, the Rest of Asia Pacific, the Rest of Latin America, and the Rest of Middle East & Africa | Enhanced regional granularity through additional country-level segmentation, including Germany, the UK, France, Italy, Spain, and the Rest of Europe; China, Japan, India, and the Rest of Asia Pacific; Brazil, Mexico, and the Rest of Latin America, along with dedicated analysis for the Middle East & Africa |
| Pricing analysis of multiplex assay consumables and instruments | Country-wise regulatory and reimbursement landscape analysis for multiplex assays | Broadened market segmentation framework with the inclusion of NGS under the Technology segment, along with refined End User categorization covering Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and the newly added Contract Research Organization (CROs) |
RECENT DEVELOPMENTS
- April 2026 : Thermo Fisher Scientific Inc. (US) has unveiled a VeriFlex-enabled thermal cycler that can perform multiplex assay protocols simultaneously using 3 x 32-well configurations.
- March 2026 : bioMérieux (France) announced IVDR CE marking for BIOFIRE SPOTFIRE R/ST plus Panels, enabling near-patient point-of-care multiplex PCR testing to detect common respiratory and sore throat pathogens within typical patient visit timeframes across European markets.
- February 2026 : Waters Corporation (US) successfully merged with Becton, Dickinson and Company’s (US) Biosciences and Diagnostic Solutions businesses, enhancing its multiplex assay capabilities through flow cytometry, cellular analysis, and diagnostic testing platforms.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
4
MARKET OVERVIEW
49
4.2.1.1
RISING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES
4.2.1.2
ADVANTAGES OVER SINGLEPLEX AND TRADITIONAL ASSAYS
4.2.1.3
INCREASING USE OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS
4.2.1.4
GROWING FOCUS ON EARLY DISEASE DETECTION
4.2.1.5
EXPANSION OF BIOMARKER-DRIVEN RESEARCH
4.2.2.1
COST CONSTRAINTS ASSOCIATED WITH MULTIPLEX ASSAY INSTRUMENTATION
4.2.2.2
REGULATORY CHALLENGES AND STRINGENT QUALITY STANDARDS
4.2.3.1
GROWING VALIDATION OF BIOMARKERS IN MOLECULAR AND PROTEIN-BASED DIAGNOSTICS
4.2.3.2
EXPANSION IN EMERGING MARKETS
4.2.4.1
SHORTAGE OF SKILLED PROFESSIONALS
4.2.4.2
COMPLEX DATA ANALYSIS AND INTERPRETATION
4.3
UNMET NEEDS AND WHITE SPACES
4.3.1
UNMET NEEDS IN MULTIPLEX ASSAY MARKET
4.3.2
WHITE SPACE OPPORTUNITIES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1
INTERCONNECTED MARKETS
4.4.2
CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1
KEY MOVES AND STRATEGIC FOCUS
5
INDUSTRY TRENDS
63
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
BARGAINING POWER OF SUPPLIERS
5.1.2
BARGAINING POWER OF BUYERS
5.1.3
THREAT OF NEW ENTRANTS
5.1.4
THREAT OF SUBSTITUTES
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC INDICATORS
5.2.2
GDP TRENDS AND FORECAST
5.3
SUPPLY CHAIN ANALYSIS
5.5.1
MULTIPLEX ASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
5.6.1
AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026
5.6.2
AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026
5.7.1
IMPORT SCENARIO (HS CODE 3822)
5.7.2
EXPORT SCENARIO (HS CODE 3822)
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.11
IMPACT OF 2025 US TARIFF ON MULTIPLEX ASSAY MARKET
5.11.3
PRICE IMPACT ANALYSIS
5.11.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
82
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
MULTIPLEX REAL-TIME PCR
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
ADJACENT TECHNOLOGIES
6.3.1
NEXT-GENERATION SEQUENCING
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.5.1
LIST OF KEY PATENTS
6.7
IMPACT OF AI/GENERATIVE AI ON MULTIPLEX ASSAY MARKET
6.7.2
TOP USE CASES AND MARKET POTENTIAL
6.7.3
KEY COMPANIES IMPLEMENTING AI
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
92
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAYS
7.2.1.1
ECO-FRIENDLY INITIATIVES
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
8
CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
96
8.1
DECISION-MAKING PROCESS
8.2
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.3
ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4
UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5.3
MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9
MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE
102
9.2.1
RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
9.3.1
LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
9.4.1
INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE
10
MULTIPLEX ASSAY MARKET, BY TYPE
113
10.2
PROTEIN MULTIPLEX ASSAYS
10.2.1
BEAD-BASED PROTEIN ASSAYS
10.2.1.1
BEST SUITED TO STUDY PROTEIN-PROTEIN INTERACTIONS
10.2.2
PLANAR PROTEIN ASSAYS
10.2.2.1
PIVOTAL ROLE IN DRUG DISCOVERY TO SUPPORT UPTAKE
10.2.3
OTHER PROTEIN ASSAYS
10.3
NUCLEIC ACID MULTIPLEX ASSAYS
10.3.1
BEAD-BASED NUCLEIC ACID ASSAYS
10.3.1.1
INCREASING INFECTIOUS DISEASES AND GENETIC SCREENING TESTS TO DRIVE MARKET
10.3.2
PLANAR NUCLEIC ACID ASSAYS
10.3.2.1
PLANAR MULTIPLEX ASSAYS PREFERRED IN GENE EXPRESSION ANALYSIS, SNP GENOTYPING, AND TRANSCRIPTOME ANALYSIS
10.3.3
OTHER NUCLEIC ACID ASSAYS
10.4
CELL-BASED MULTIPLEX ASSAYS
10.4.1
BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET
11
MULTIPLEX ASSAY MARKET, BY TECHNOLOGY
141
11.2.1
WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO DRIVE SEGMENT
11.3
FLUORESCENCE DETECTION
11.3.1
INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL SEGMENT GROWTH
11.4
MULTIPLEX REAL-TIME PCR
11.4.1
HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
11.5.1
RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
11.6
NEXT-GENERATION SEQUENCING (NGS)
11.6.1
RISING ADOPTION OF CUSTOMIZED AND APPLICATION-SPECIFIC NGS MULTIPLEX PANELS TO DRIVE MARKET
12
MULTIPLEX ASSAY MARKET, BY APPLICATION
161
12.2
RESEARCH & DEVELOPMENT
12.2.1
DRUG DISCOVERY & DEVELOPMENT
12.2.1.1
MULTIPLEX ASSAYS MASSIVELY EMPLOYED IN PRECLINICAL AND CLINICAL PHASES
12.2.2
BIOMARKER DISCOVERY & VALIDATION
12.2.2.1
ADVANCING BIOMARKER DISCOVERY THROUGH GLOBAL COLLABORATIVE RESEARCH NETWORKS
12.3
CLINICAL DIAGNOSTICS
12.3.1
INFECTIOUS DISEASES
12.3.1.1
GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE UPTAKE OF MULTIPLEX ASSAYS
12.3.2.1
RISING BURDEN OF CANCER TO DRIVE MARKET
12.3.3
CARDIOVASCULAR DISEASES
12.3.3.1
HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH
12.3.4
AUTOIMMUNE DISEASES
12.3.4.1
HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE DEMAND FOR MEASURES PROMOTING EARLY DIAGNOSIS
12.3.5
NERVOUS SYSTEM DISORDERS
12.3.5.1
GROWING PREVALENCE OF NERVOUS SYSTEM DISORDERS TO FUEL UPTAKE OF MULTIPLEX ASSAYS FOR EARLY DIAGNOSIS AND TREATMENT
12.3.6
METABOLISM & ENDOCRINOLOGY DISORDERS
12.3.6.1
MULTIPLEX ASSAYS USED TO MEASURE ENDOCRINE AND METABOLIC BIOMARKERS HELP IN TIMELY DIAGNOSIS
13
MULTIPLEX ASSAY MARKET, BY END USER
196
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1
GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE MARKET
13.3
HOSPITALS & DIAGNOSTIC LABORATORIES
13.3.1
INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
13.4
ACADEMIC & RESEARCH INSTITUTES
13.4.1
RISING GOVERNMENT FUNDING TO ACCELERATE MULTIPLEX ADOPTION IN ACADEMIC RESEARCH
13.5
CONTRACT RESEARCH ORGANIZATIONS
13.5.1
RISING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES TO ACCELERATE MULTIPLEX ASSAY ADOPTION AMONG CROS
14
MULTIPLEX ASSAY MARKET, BY REGION
213
14.2.1.1
INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET
14.2.2.1
FAVORABLE GOVERNMENT INITIATIVES TO FUEL MARKET
14.3.1.1
STRONG HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
14.3.2.1
EXPANSION OF DIAGNOSTIC INFRASTRUCTURE TO DRIVE MARKET
14.3.3.1
STRONG R&D INVESTMENTS AND GROWING DISEASE BURDEN TO DRIVE MARKET
14.3.4.1
GROWING ADOPTION OF ADVANCED DIAGNOSTICS TO DRIVE MARKET
14.3.5.1
RISING DISEASE BURDEN TO DRIVE MARKET
14.4.1.1
STRONG HEALTHCARE INVESTMENTS TO DRIVE MARKET
14.4.2.1
UNIVERSAL HEALTHCARE REIMBURSEMENT POLICY TO FOSTER MARKET GROWTH
14.4.3.1
INCREASED PRIVATE AND PUBLIC INVESTMENTS TO BOLSTER GROWTH
14.4.4
REST OF ASIA PACIFIC
14.5.1.1
RISING DISEASE BURDEN AND EXPANDING RESEARCH ECOSYSTEM TO DRIVE MARKET
14.5.2.1
RISING CHRONIC DISEASE BURDEN TO DRIVE MARKET
14.5.3
REST OF LATIN AMERICA
14.6
MIDDLE EAST & AFRICA
14.6.1
GROWING HEALTHCARE INVESTMENTS AND RISING DEMAND FOR MULTIPLEX TESTING TO DRIVE MARKET
15
COMPETITIVE LANDSCAPE
303
15.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026
15.2.1
OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MULTIPLEX ASSAY MARKET
15.3
REVENUE ANALYSIS, 2023–2025
15.4
MARKET SHARE ANALYSIS, 2025
15.4.1
MARKET SHARE ANALYSIS, 2025
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1
COMPANY FOOTPRINT
15.5.5.2
REGION FOOTPRINT
15.5.5.3
PRODUCT & SERVICE FOOTPRINT
15.5.5.4
APPLICATION FOOTPRINT
15.5.5.5
END USER FOOTPRINT
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1
PROGRESSIVE COMPANIES
15.6.2
RESPONSIVE COMPANIES
15.6.5
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (1/2)
15.6.5.3
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (2/2)
15.7
COMPANY VALUATION AND FINANCIAL METRICS
15.8
BRAND/PRODUCT COMPARISON
15.9
COMPETITIVE SCENARIO
15.9.1
PRODUCT LAUNCHES & APPROVALS
16
COMPANY PROFILES
322
16.1.1.1
BUSINESS OVERVIEW
16.1.1.2
PRODUCTS OFFERED
16.1.1.3
RECENT DEVELOPMENTS
16.1.1.3.1
PRODUCT LAUNCHES & APPROVALS
16.1.1.4.2
STRATEGIC CHOICES
16.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
16.1.2
BIO-RAD LABORATORIES, INC.
16.1.3
THERMO FISHER SCIENTIFIC INC.
16.1.6
BECTON, DICKINSON AND COMPANY
16.1.9
AGILENT TECHNOLOGIES, INC.
16.1.10
DANAHER CORPORATION
16.1.12
F. HOFFMANN-LA ROCHE LTD
16.1.13
QUANTERIX CORPORATION
16.2.1
BIO-TECHNE CORPORATION
16.2.3
MESO SCALE DIAGNOSTICS LLC
16.2.4
RANDOX LABORATORIES LTD.
16.2.5
STANDARD BIOTOOLS INC.
16.2.7
ABBOTT LABORATORIES
16.2.8
SIEMENS HEALTHINEERS AG
16.2.10
SHIMADZU CORPORATION
16.2.11
PROMEGA CORPORATION
16.2.12
BOSTER BIOLOGICAL TECHNOLOGY
17
RESEARCH METHODOLOGY
389
17.1.1
SECONDARY RESEARCH
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
17.1.2.2
KEY DATA FROM PRIMARY SOURCES
17.1.2.3
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.1.1
APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
17.2.1.2
APPROACH 2: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
17.3
MARKET BREAKDOWN AND DATA TRIANGULATION
17.4
MARKET SHARE ANALYSIS
17.5
RESEARCH ASSUMPTIONS
17.5.1
PARAMETRIC ASSUMPTIONS
17.5.2
GROWTH RATE ASSUMPTIONS
17.6
RESEARCH LIMITATIONS
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
TABLE 1
ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV (ALL AGES): 2010, 2023, AND 2024 (MILLION PEOPLE)
TABLE 2
ESTIMATED NUMBER OF NEW CANCER CASES IN BOTH SEXES: AGE 0-85+, 2022–2045
TABLE 3
TOTAL TB INCIDENCE, 2024
TABLE 4
IMPACT OF PORTER’S FIVE FORCES ON MULTIPLEX ASSAY MARKET
TABLE 5
GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 6
NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 7
EUROPE: MACROECONOMIC INDICATORS
TABLE 8
ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 9
LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 10
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 11
AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026 (USD)
TABLE 12
AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 13
IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 14
EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 15
MULTIPLEX ASSAY MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 16
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 17
KEY PATENTS IN MULTIPLEX ASSAY MARKET, 2022–2026
TABLE 18
KEY COMPANIES IMPLEMENTING AI IN MULTIPLEX ASSAY MARKET
TABLE 19
NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20
EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21
ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22
LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23
REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 25
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
TABLE 26
ADOPTION BARRIERS AND INTERNAL CHALLENGES
TABLE 27
MULTIPLEX ASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 28
MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 29
MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 30
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31
EUROPE: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34
GLOBAL: NUMBER OF MULTIPLEX ANALYZERS INSTALLED, 2024–2031 (UNITS)
TABLE 35
MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 36
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37
EUROPE: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40
MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 41
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
EUROPE: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45
MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 46
MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 47
MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 48
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
EUROPE: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52
MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 53
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57
MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 58
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62
MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 63
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64
EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67
SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA
TABLE 68
MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 69
MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 70
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71
EUROPE: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74
MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 75
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76
EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79
MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 80
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84
MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 85
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89
MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 90
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91
EUROPE: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 95
MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 96
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97
EUROPE: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 101
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102
EUROPE: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105
MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 106
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107
EUROPE: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110
MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY REGION, 2024–2031 (USD MILLION)
TABLE 111
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112
EUROPE: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115
MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2024–2031 (USD MILLION)
TABLE 116
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117
EUROPE: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120
MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 121
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122
EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125
MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 126
MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127
MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 128
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129
EUROPE: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132
MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 133
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134
EUROPE: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137
MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 138
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139
EUROPE: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142
MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143
MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 144
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145
EUROPE: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148
MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 149
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150
EUROPE: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153
ESTIMATED NUMBER OF CANCER CASES IN BOTH SEXES (AGE 0-85+), BY REGION, 2022 VS. 2030
TABLE 154
MULTIPLEX ASSAY MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 155
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156
EUROPE: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159
MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 160
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161
EUROPE: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164
MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 165
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166
EUROPE: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169
MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 170
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171
EUROPE: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174
MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 175
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176
EUROPE: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179
MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 180
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181
EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184
MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 185
MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 186
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187
EUROPE: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190
MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 191
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192
EUROPE: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195
MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 196
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197
EUROPE: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200
MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 201
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202
EUROPE: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205
MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 206
NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207
EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208
ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209
LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210
MULTIPLEX ASSAY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 211
NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
TABLE 212
NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 213
NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214
NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 215
NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 216
NORTH AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217
NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218
NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 219
NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 220
NORTH AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221
NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222
NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 223
US: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 224
US: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225
US: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226
US: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227
US: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 228
US: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 229
US: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230
US: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231
US: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 232
CANADA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 233
CANADA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 234
CANADA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 235
CANADA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236
CANADA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 237
CANADA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 238
CANADA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239
CANADA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 240
CANADA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 241
EUROPE: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
TABLE 242
MACROECONOMIC INDICATORS FOR EUROPE
TABLE 243
EUROPE: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244
EUROPE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 245
EUROPE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 246
EUROPE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 247
EUROPE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 248
EUROPE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 249
EUROPE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 250
EUROPE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251
EUROPE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252
EUROPE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 253
GERMANY: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 254
GERMANY: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255
GERMANY: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 256
GERMANY: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 257
GERMANY: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 258
GERMANY: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 259
GERMANY: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 260
GERMANY: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 261
GERMANY: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 262
UK: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 263
UK: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 264
UK: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 265
UK: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266
UK: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 267
UK: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 268
UK: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269
UK: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270
UK: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 271
FRANCE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 272
FRANCE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273
FRANCE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274
FRANCE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 275
FRANCE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 276
FRANCE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 277
FRANCE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 278
FRANCE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 279
FRANCE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 280
ITALY: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 281
ITALY: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 282
ITALY: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 283
ITALY: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 284
ITALY: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 285
ITALY: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 286
ITALY: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287
ITALY: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288
ITALY: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 289
SPAIN: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 290
SPAIN: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 291
SPAIN: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 292
SPAIN: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 293
SPAIN: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 294
SPAIN: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 295
SPAIN: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296
SPAIN: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297
SPAIN: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 298
REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 299
REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 300
REST OF EUROPE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301
REST OF EUROPE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302
REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 303
REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 304
REST OF EUROPE: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 305
REST OF EUROPE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 306
REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 307
MACROECONOMIC INDICATORS FOR ASIA PACIFIC
TABLE 308
ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309
ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 310
ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 311
ASIA PACIFIC: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312
ASIA PACIFIC: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 313
ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 314
ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 315
ASIA PACIFIC: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316
ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 317
ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 318
CHINA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 319
CHINA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 320
CHINA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321
CHINA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 322
CHINA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 323
CHINA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 324
CHINA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 325
CHINA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 326
CHINA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 327
JAPAN: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 328
JAPAN: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 329
JAPAN: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 330
JAPAN: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 331
JAPAN: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 332
JAPAN: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 333
JAPAN: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 334
JAPAN: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 335
JAPAN: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 336
INDIA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 337
INDIA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 338
INDIA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 339
INDIA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 340
INDIA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 341
INDIA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 342
INDIA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 343
INDIA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 344
INDIA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 345
REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 346
REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 347
REST OF ASIA PACIFIC: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 348
REST OF ASIA PACIFIC: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 349
REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 350
REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 351
REST OF ASIA PACIFIC: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 352
REST OF ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 353
REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 354
MACROECONOMIC INDICATORS FOR LATIN AMERICA
TABLE 355
LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 356
LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 357
LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 358
LATIN AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 359
LATIN AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 360
LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 361
LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 362
LATIN AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 363
LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 364
LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 365
BRAZIL: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 366
BRAZIL: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 367
BRAZIL: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 368
BRAZIL: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 369
BRAZIL: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 370
BRAZIL: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 371
BRAZIL: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 372
BRAZIL: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 373
BRAZIL: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 374
MEXICO: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 375
MEXICO: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 376
MEXICO: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 377
MEXICO: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 378
MEXICO: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 379
MEXICO: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 380
MEXICO: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 381
MEXICO: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 382
MEXICO: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 383
REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 384
REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 385
REST OF LATIN AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 386
REST OF LATIN AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 387
REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 388
REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 389
REST OF LATIN AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 390
REST OF LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 391
REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 392
MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 393
MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 394
MIDDLE EAST & AFRICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 395
MIDDLE EAST & AFRICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 396
MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 397
MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 398
MIDDLE EAST & AFRICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 399
MIDDLE EAST & AFRICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 400
MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 401
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN MULTIPLEX ASSAY MARKET, JANUARY 2023−APRIL 2026
TABLE 402
MULTIPLEX ASSAY MARKET: DEGREE OF COMPETITION
TABLE 403
MULTIPLEX ASSAY MARKET: REGION FOOTPRINT
TABLE 404
MULTIPLEX ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 405
MULTIPLEX ASSAY MARKET: APPLICATION FOOTPRINT
TABLE 406
MULTIPLEX ASSAY MARKET: END USER FOOTPRINT
TABLE 407
MULTIPLEX ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 408
MULTIPLEX ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (1/2)
TABLE 409
MULTIPLEX ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (2/2)
TABLE 410
MULTIPLEX ASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 411
MULTIPLEX ASSAY MARKET: DEALS, JANUARY 2023–APRIL 2026
TABLE 412
MERCK KGAA: EXPANSIONS, JANUARY 2023– APRIL 2026
TABLE 413
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 414
ILLUMINA, INC: PRODUCTS OFFERED
TABLE 415
ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 416
ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 417
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 418
BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 419
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 420
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 421
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 422
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 423
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 424
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 425
DIASORIN S.P.A.: COMPANY OVERVIEW
TABLE 426
DIASORIN S.P.A.: PRODUCTS OFFERED
TABLE 427
DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 428
DIASORIN S.P.A.: DEALS, JANUARY 2023–APRIL 2026
TABLE 429
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 430
BIOMÉRIEUX: PRODUCTS OFFERED
TABLE 431
BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 432
BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026
TABLE 433
BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
TABLE 434
BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
TABLE 435
BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 436
BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2023–APRIL 2026
TABLE 437
QIAGEN N.V.: COMPANY OVERVIEW
TABLE 438
QIAGEN N.V.: PRODUCTS OFFERED
TABLE 439
QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 440
QIAGEN N.V.: DEALS, JANUARY 2023–APRIL 2026
TABLE 441
MERCK KGAA: COMPANY OVERVIEW
TABLE 442
MERCK KGAA: PRODUCTS OFFERED
TABLE 443
MERCK KGAA: DEALS, JANUARY 2023–APRIL 2026
TABLE 444
MERCK KGAA: DEALS, JANUARY 2023– APRIL 2026
TABLE 445
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 446
AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 447
AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 448
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 449
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 450
DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 451
DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 452
DANAHER CORPORATION: DEALS, JANUARY 2023–APRIL 2026
TABLE 453
REVVITY, INC.: COMPANY OVERVIEW
TABLE 454
REVVITY, INC.: PRODUCTS OFFERED
TABLE 455
REVVITY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 456
REVVITY, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 457
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 458
F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 459
F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 460
F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023–APRIL 2026
TABLE 461
QUANTERIX CORPORATION: COMPANY OVERVIEW
TABLE 462
QUANTERIX CORPORATION: PRODUCTS OFFERED
TABLE 463
QUANTERIX CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 464
QUANTERIX CORPORATION: DEALS, JANUARY 2023–APRIL 2026
TABLE 465
BIO-TECHNE CORPORATION: COMPANY OVERVIEW
TABLE 466
SEEGENE INC.: COMPANY OVERVIEW
TABLE 467
MESO SCALE DIAGNOSTICS LLC: COMPANY OVERVIEW
TABLE 468
RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
TABLE 469
STANDARD BIOTOOLS INC.: COMPANY OVERVIEW
TABLE 470
HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 471
ABBOTT LABORATORIES: COMPANY OVERVIEW
TABLE 472
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 473
ENZO BIOCHEM INC.: COMPANY OVERVIEW
TABLE 474
SHIMADZU CORPORATION: COMPANY OVERVIEW
TABLE 475
PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 476
BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
TABLE 477
MULTIPLEX ASSAY MARKET: RISK ASSESSMENT
FIGURE 1
MULTIPLEX ASSAY MARKET SEGMENTATION
FIGURE 2
MARKET HIGHLIGHTS AND KEY INSIGHTS
FIGURE 3
MULTIPLEX ASSAY MARKET, 2024–2031
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025
FIGURE 5
DISRUPTIVE TRENDS IMPACTING GROWTH OF MULTIPLEX ASSAY MARKET
FIGURE 6
HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN MULTIPLEX ASSAY MARKET, 2026-2031
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 8
RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
FIGURE 9
CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 10
PROTEIN MULTIPLEX ASSAYS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 11
MULTIPLEX REAL-TIME PCR SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 12
RESEARCH & DEVELOPMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 15
MULTIPLEX ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 16
MULTIPLEX ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 17
MULTIPLEX ASSAY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 18
MULTIPLEX ASSAY MARKET: VALUE CHAIN ANALYSIS
FIGURE 19
MULTIPLEX ASSAY MARKET: ECOSYSTEM ANALYSIS
FIGURE 20
MULTIPLEX ASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 21
NUMBER OF DEALS AND FUNDING ACTIVITIES IN MULTIPLEX ASSAY MARKET
FIGURE 22
APPLIED AND GRANTED PATENTS, 2016–2025
FIGURE 23
MARKET POTENTIAL OF AI IN MULTIPLEX ASSAY MARKET
FIGURE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 25
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
FIGURE 26
NORTH AMERICA: MULTIPLEX ASSAY MARKET SNAPSHOT
FIGURE 27
ASIA PACIFIC: MULTIPLEX ASSAY MARKET SNAPSHOT
FIGURE 28
REVENUE ANALYSIS OF KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025 (USD MILLION)
FIGURE 29
MULTIPLEX ASSAY MARKET SHARE ANALYSIS, 2025
FIGURE 30
MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 31
MULTIPLEX ASSAY MARKET: COMPANY FOOTPRINT
FIGURE 32
MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 33
EV/EBITDA OF KEY VENDORS
FIGURE 34
YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 35
MULTIPLEX ASSAY MARKET: BRAND/PRODUCT COMPARISON FOR MULTIPLEX INSTRUMENTS
FIGURE 36
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 38
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 39
DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
FIGURE 40
BIOMÉRIEUX: COMPANY SNAPSHOT (2025)
FIGURE 41
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025)
FIGURE 42
QIAGEN N.V.: COMPANY SNAPSHOT (2025)
FIGURE 43
MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 44
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 45
DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 46
REVVITY, INC.: COMPANY SNAPSHOT (2025)
FIGURE 47
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 48
QUANTERIX CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 49
RESEARCH DESIGN
FIGURE 50
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 51
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 52
MULTIPLEX ASSAY MARKET: REVENUE SHARE ANALYSIS
FIGURE 53
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 54
TOP-DOWN APPROACH
FIGURE 55
DATA TRIANGULATION METHODOLOGY
Methodology
The objective of this study is to analyze key market dynamics, including drivers, opportunities, restraints, and challenges, as well as the strategies of major players. It aims to monitor developments across leading players, including acquisitions, product launches, expansions, agreements, and partnerships. Additionally, the study will examine the competitive landscape of the multiplex assay market by evaluating market participants based on various criteria within the overarching categories of business and product strategy. To estimate the market size, both top-down and bottom-up approaches were employed. The market breakdown and data triangulation methods were used to assess segment and subsegment sizes.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were primarily industry experts from core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. The tiers are as follows: Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
For the global market value, annual revenue figures were calculated using revenue mapping for major product manufacturers and OEMs active in the global multiplex assay market. All major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. Also, the global multiplex assay market was split into various segments and sub-segments:
- List of major players operating in the products market at the regional and/or country level
- Product mapping of various multiplex assay manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from multiplex assay (or the nearest reported business unit/product category)
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global multiplex assay market
The data mentioned above was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
Market Size Estimation (Bottom-up & Top-down Approaches)
Data Triangulation
After determining the overall size of the global multiplex assay market using the methodology described above, the market was segmented into several segments and subsegments. The data triangulation and market breakdown procedures were employed, as applicable, to complete the overall market engineering process and obtain exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.
Market Definition
The multiplex assay market comprises analytical testing platforms that enable the qualitative and quantitative assessment of multiple analytes from a single biological sample in a single run. These platforms offer advantages such as reduced testing time, increased automation, and the need for fewer biological samples compared to singleplex assays. The industry encompasses instrumentation, reagents, software, and other services utilized for a wide range of applications globally.
Key Stakeholders
- Manufacturers of multiplex assay products
- Suppliers and distributors of multiplex assay products
- Hospitals
- Diagnostic, clinical, and research laboratories
- Research & development (R&D) companies
- Group purchasing organizations (GPOs)
- Medical research laboratories
- Academic medical centers and universities
- Corporate entities
- Accountable care organizations (ACOs)
- Community centers
- Government institutes
- Market research and consulting firms
- Contract manufacturing organizations (CMOs)
- Contract research organizations (CROs)
- Venture capitalists and investors
Report Objectives
- To define, describe, segment, and forecast the multiplex assay market by product & service, type, technology, application, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiplex assay market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the multiplex assay market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the multiplex assay market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the multiplex assay market
- To benchmark players within the multiplex assay market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Available customizations:
Based on the given market data, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
- Further breakdown of the Rest of Europe multiplex assay market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the Rest of Asia Pacific multiplex assay market into South Korea, Taiwan, and others
- Further breakdown of the Rest of Latin America multiplex assay market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Southeast Asia multiplex assay market into Malaysia, Singapore, Australia, New Zealand, and others
COMPETITIVE LANDSCAPE ASSESSMENT
- Market Share Analysis, by region (North America and Europe), which provides the market share of the top 3 to 5 key players in the multiplex assay market
- Competitive leadership mapping for established players in the US
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Previous Next